PBLA Panbela Therapeutics
- 0.410
- -0.030-6.82%
Panbela Therapeutics News
Panbela Therapeutics Announces Delay of Expected Data From Pancreatic Cancer Treatment Trial
Panbela Therapeutics Updates ASPIRE Trial Timeline
Panbela Applies to List on CBOE
By Stephen Nakrosis Panbela Therapeutics, whose shares were recently delisted from the Nasdaq, said Thursday it will seek to list on the US Equity Listings Tier II Chicago Board of Options Exchange.
Panbela Therapeutics, Recently Delisted From Nasdaq and Now on OTCQB, to Seek CBOE Stock Listing
Panbela Therapeutics, Recently Delisted From Nasdaq and Now on OTCQB, to Seek CBOE Stock Listing
Panbela Therapeutics Files for Stock and Warrant Offering
Panbela Therapeutics Files for Stock and Warrant Offering
Panbela Therapeutics Shifts From Nasdaq to OTCQB Market
Panbela Announces Transfer to OTCQB Market
Panbela Therapeutics, Inc. (OTCQB: PBLA), today announced that its common stock has been approved for quotation on the OTCQB market. Panbela's common stock will be eligible for quotation on the OTCQB starting on April 17, 2024, under the symbol "PBLA."
Panbela Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Panbela Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Panbela Therapeutics, Lowers Price Target to $5
HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price target from $16 to $5.
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)
Roth MKM Maintains Buy on Panbela Therapeutics, Maintains $25 Price Target
Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.
Earnings Call Summary | Panbela Therapeutics(PBLA.US) Q4 2023 Earnings Conference
The following is a summary of the Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript:Financial Performance:Panbela's general and administrative expenses were down to $0.9 million due t
Press Release: Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Panbela Therapeutics, Inc. (NASDAQ:PBLA) today provides a business update and reports financial results for the quarter and full year ended December 31, 2023.
Recap: Panbela Therapeutics Q4 Earnings
Panbela Therapeutics (OTC:PBLA) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:10 PM.Here's what investors need to know about the announcement.EarningsPanbela Therapeutics missed es
Panbela Therapeutics GAAP EPS of -$65.90 Beats by $151.10
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Panbela Therapeutics, Inc. (NASDAQ:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
Nasdaq to Delist Panbela Therapeutics Over Equity Shortfall
Top 4 Health Care Stocks That Are Preparing To Pump This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Panbela Regains Nasdaq Compliance
Panbela Regains Nasdaq Compliance
Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"
Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For
Analysis
Price Target
No Data
